126 related articles for article (PubMed ID: 2400642)
1. Chemical synthesis, absolute configuration, and stereochemistry of formation of 10-hydroxywarfarin: a major oxidative metabolite of (+)-(R)-warfarin from hepatic microsomal preparations.
Lawrence RF; Rettie AE; Eddy AC; Trager WF
Chirality; 1990; 2(2):96-105. PubMed ID: 2400642
[TBL] [Abstract][Full Text] [Related]
2. Human hepatic cytochrome P-450 composition as probed by in vitro microsomal metabolism of warfarin.
Kaminsky LS; Dunbar DA; Wang PP; Beaune P; Larrey D; Guengerich FP; Schnellmann RG; Sipes IG
Drug Metab Dispos; 1984; 12(4):470-7. PubMed ID: 6148215
[TBL] [Abstract][Full Text] [Related]
3. Substrate probes for the mechanism of aromatic hydroxylation catalyzed by cytochrome P-450: selectively deuterated analogues of warfarin.
Bush ED; Trager WF
J Med Chem; 1985 Aug; 28(8):992-6. PubMed ID: 4020838
[TBL] [Abstract][Full Text] [Related]
4. Warfarin: stereochemical aspects of its metabolism in vivo in the rat.
Pohl LR; Bales R; Trager WF
Res Commun Chem Pathol Pharmacol; 1976 Oct; 15(2):233-56. PubMed ID: 981784
[TBL] [Abstract][Full Text] [Related]
5. Phase II metabolism of warfarin in primary culture of adult rat hepatocytes.
Jansing RL; Chao ES; Kaminsky LS
Mol Pharmacol; 1992 Jan; 41(1):209-15. PubMed ID: 1732719
[TBL] [Abstract][Full Text] [Related]
6. Substrate probe for the mechanism of aromatic hydroxylation catalyzed by cytochrome P450.
Darbyshire JF; Iyer KR; Grogan J; Korzekwa KR; Trager WF
Drug Metab Dispos; 1996 Sep; 24(9):1038-45. PubMed ID: 8886617
[TBL] [Abstract][Full Text] [Related]
7. Cytochrome P450-dependent transformations of 15R- and 15S-hydroperoxyeicosatetraenoic acids: stereoselective formation of epoxy alcohol products.
Chang MS; Boeglin WE; Guengerich FP; Brash AR
Biochemistry; 1996 Jan; 35(2):464-71. PubMed ID: 8555216
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of warfarin hydroxylation catalyzed by human liver microsomes.
Rettie AE; Eddy AC; Heimark LD; Gibaldi M; Trager WF
Drug Metab Dispos; 1989; 17(3):265-70. PubMed ID: 2568906
[TBL] [Abstract][Full Text] [Related]
9. A new warfarin metabolite: structure and function.
Fasco MJ; Dymerski PP; Wos JD; Kaminsky LS
J Med Chem; 1978 Oct; 21(10):1054-9. PubMed ID: 722713
[TBL] [Abstract][Full Text] [Related]
10. Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A.
Niwa T; Shiraga T; Mitani Y; Terakawa M; Tokuma Y; Kagayama A
Drug Metab Dispos; 2000 Sep; 28(9):1128-34. PubMed ID: 10950860
[TBL] [Abstract][Full Text] [Related]
11. Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe.
Kaminsky LS; de Morais SM; Faletto MB; Dunbar DA; Goldstein JA
Mol Pharmacol; 1993 Feb; 43(2):234-9. PubMed ID: 8429826
[TBL] [Abstract][Full Text] [Related]
12. Selective inhibition of warfarin metabolism by diltiazem in humans.
Abernethy DR; Kaminsky LS; Dickinson TH
J Pharmacol Exp Ther; 1991 Apr; 257(1):411-5. PubMed ID: 2020000
[TBL] [Abstract][Full Text] [Related]
13. Genetic and developmental diversity of hepatic cytochromes P450. Warfarin and progesterone metabolism by hepatic microsomes from four inbred strains of rat.
Kitareewan S; Walz FG
Drug Metab Dispos; 1994; 22(4):607-15. PubMed ID: 7956737
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous determination of warfarin enantiomers and its metabolite in human plasma by column-switching high-performance liquid chromatography with chiral separation.
Uno T; Niioka T; Hayakari M; Sugawara K; Tateishi T
Ther Drug Monit; 2007 Jun; 29(3):333-9. PubMed ID: 17529891
[TBL] [Abstract][Full Text] [Related]
15. Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies.
Kunze KL; Wienkers LC; Thummel KE; Trager WF
Drug Metab Dispos; 1996 Apr; 24(4):414-21. PubMed ID: 8801056
[TBL] [Abstract][Full Text] [Related]
16. Regioselectivity significantly impacts microsomal glucuronidation efficiency of R/S-6, 7-, and 8-hydroxywarfarin.
Kim SY; Jones DR; Kang JY; Yun CH; Miller GP
Xenobiotica; 2019 Apr; 49(4):397-403. PubMed ID: 29543105
[TBL] [Abstract][Full Text] [Related]
17. Quantitative liquid chromatography/mass spectrometry/mass spectrometry warfarin assay for in vitro cytochrome P450 studies.
Zhang ZY; King BM; Wong YN
Anal Biochem; 2001 Nov; 298(1):40-9. PubMed ID: 11673893
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome P450 responsible for the stereoselective S-oxidation of flosequinan in hepatic microsomes from rats and humans.
Kashiyama E; Yokoi T; Odomi M; Funae Y; Inoue K; Kamataki T
Drug Metab Dispos; 1997 Jun; 25(6):716-24. PubMed ID: 9193873
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of (S)-warfarin metabolism by sulfinpyrazone and its metabolites.
He M; Kunze KL; Trager WF
Drug Metab Dispos; 1995 Jun; 23(6):659-63. PubMed ID: 7587949
[TBL] [Abstract][Full Text] [Related]
20. Hydroxywarfarin metabolites potently inhibit CYP2C9 metabolism of S-warfarin.
Jones DR; Kim SY; Guderyon M; Yun CH; Moran JH; Miller GP
Chem Res Toxicol; 2010 May; 23(5):939-45. PubMed ID: 20429590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
